A prognostic score based on clinical factors and biomarkers for advanced non-small cell lung cancer

Trapé, Jaume; Montesinos, J.; Catot, Sílvia; Buxó, J; Franquesa, Josefina; Sala, María; Domènech, Montserrat; Sant, Francesc; Badal, Josep; Arnau, Anna

doi:10.5301/jbm.2012.9314

Cited by 17 publications

(9 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Trape et al developed an AFP scoring system that revealed similar results to our study. In their study, the median OS rates of patients who received CT were 15, 7, and 5 months in AFP 0–1, AFP 2–3 and AFP 4–5 groups, respectively, versus 8, 6, and 2 months in patients who did not receive any CT [8] . The median PFS was 10 months in the LPI 0 group and 5 months in the LPI 2 group.…”

Section: Discussionmentioning

confidence: 92%

A Laboratory Prognostic Index Model for Patients with Advanced Non-Small Cell Lung Cancer

et al. 2014

View full text Add to dashboard Cite

PurposeWe aimed to establish a laboratory prognostic index (LPI) in advanced non-small cell lung cancer (NSCLC) patients based on hematologic and biochemical parameters and to analyze the predictive value of LPI on NSCLC survival.Patients and MethodsThe study retrospectively reviewed 462 patients with advanced NSCLC diagnosed between 2000 and 2010 in a single institution. We developed an LPI that included serum levels of white blood cells (WBC), lactate dehydrogenase (LDH), albumin, calcium, and alkaline phosphatase (ALP), based on the results of a Cox regression analysis. The patients were classified into 3 LPI groups as follows: LPI 0: normal; LPI 1: one abnormal laboratory finding; and LPI 2: at least 2 abnormal laboratory findings.ResultsThe median follow up period was 44 months; the median overall survival (OS) and median progression-free survival (PFS) were 11 and 6 months, respectively. A multivariate analysis revealed that the following could be used as independent prognostic factors: an Eastern Cooperative Oncology Group performance status score (ECOG PS) ≥2, a high LDH level, serum albumin <3 g/dL, serum calcium>10.5 g/dL, number of metastases>2, presence of liver metastases, malignant pleural effusion, or receiving chemotherapy ≥4 cycles. The 1-year OS rates according to LPI 0, LPI 1, and LPI 2 were 54%, 34%, and 17% (p<0.001), respectively and 6-month PFS rates were 44%, 27%, and 15% (p<0.001), respectively. The LPI was a significant predictor for OS (Hazard Ratio (HR): 1.41; 1.05–1.88, p<0.001) and PFS (HR: 1.48; 1.14–1.93, p<0.001).ConclusionAn LPI is an inexpensive, easily accessible and independent prognostic index for advanced NSCLC and may be helpful in making individualized treatment plans and predicting survival rates when combined with clinical parameters.

show abstract

Section: Discussionmentioning

confidence: 92%

A Laboratory Prognostic Index Model for Patients with Advanced Non-Small Cell Lung Cancer

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The authors suggested that albumin and LDH levels might be used in the risk scoring in further studies. Further studies demonstrated that serum albumin level was a critical prognostic factor in the lung cancer (Forrest et al, 2003;Kasymjanova et al, 2010;Leung et al, 2012;Trape et al, 2012;Gagnon et al, 2013;Jafri et al, 2013;Ulas et al, 2014). In these studies, prognostic risk models were created using a number of clinical and laboratory variables and low serum albumin level was found to be one of the poor prognostic factors in the majority of the scoring systems.…”

Section: 5971 Serum Albumin As a Prognostic Factor With Stage Iiib Nmentioning

confidence: 99%

“…With the introduction of recent findings, the Glasgow Prognostic Score (GPS) and the Advanced Lung Cancer Inflammation Index (ALI) on the basis of serum albumin and CRP level have been developed. In addition, further scoring systems such as modified-GPS, Prognostic Index (PI), Adverse Prognostic Factors (APF), and the Montreal Prognostic Score (MPS) based on the performance status, CRP, tumor markers such as carbohydrate antigen (CA)-125, and inflammatory markers such as leukocycte and neutrophil/lymphocyte ratio have been developed (Forrest et al, 2003;Kasymjanova et al, 2010;Leung et al, 2012;Trape et al, 2012;Gagnon et al, 2013;Jafri et al, 2013;Ulas et al, 2014). In the majority of these studies, many patients had a metastatic disease (Forrest et al, 2003;Kasymjanova et al, 2010;Leung et al, 2012;Trape et al, 2012;Gagnon et al, 2013;Jafri et al, 2013;Ulas et al, 2014).…”

Section: 5971 Serum Albumin As a Prognostic Factor With Stage Iiib Nmentioning

confidence: 99%

Pretreatment Serum Albumin Level is an Independent Prognostic Factor in Patients with Stage IIIB Non-Small Cell Lung Cancer: A Study of the Turkish Descriptive Oncological Researches Group

Tanrıverdi¹,

Avcı²,

Oktay³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Subsequently, many studies investigating the role of serum CYFRA 21-1 with more updated therapeutic strategies for NSCLC and larger numbers of accrued patients have been performed16171819202122232425262728293031323334353637383940414243444546. However, these studies yielded conflicting results.…”

mentioning

confidence: 99%

Prognostic value of serum cytokeratin 19 fragments (Cyfra 21-1) in patients with non-small cell lung cancer

Qiu

et al. 2015

Sci Rep

View full text Add to dashboard Cite

The role of serum CYFRA 21-1 level in patients with non-small cell lung cancer (NSCLC) remains to be defined. To re-evaluate the impact of serum CYFRA 21-1 in NSCLC survival, we performed this meta-analysis. Databases were searched to identify relevant studies reported after the publication of a meta-analysis in 2004. Totally, 31 studies with 6394 patients were included in this meta-analysis. The pooled Hazard ratios (HRs) indicated that high CYFRA 21-1 level was associated with poor prognosis on overall survival (OS) in patients with NSCLC (HR = 1.60; 95%CI = 1.36–1.89; P < 0.001). The pooled HRs were 2.18 (95%CI = 1.70, 2.80; P = 0.347) for patients at stage I–IIIA and 1.47 (95%CI = 1.02, 2.11; P < 0.001) for stage IIIB–IV. When stratified by surgical intervention, pooled HRs were 1.94 (95%CI = 1.42–2.67; P < 0.001) for studies with surgery and 1.24 (95%CI = 0.79–1.95; P < 0.001) for studies without surgery. Significant associations were also found in the patients treated with EGFR-TKIs (HR = 1.83; 95%CI = 1.31–2.58; P = 0.011) and platinum-based regimen (HR = 1.53; 95%CI = 1.18–1.99; P = 0.001). Meta-analysis of CYFRA 21-1 related to PFS was performed and pooled HR was 1.41 (95%CI = 1.19–1.69; P < 0.001). Our results indicate that high level of serum CYFRA 21-1 is a negative prognostic indicator of patients with NSCLC.

show abstract

A prognostic score based on clinical factors and biomarkers for advanced non-small cell lung cancer

Abstract: The application of a score that includes clinical data and biomarkers may improve the prognostic classification of NSCLC patients.

Cited by 17 publications

References 15 publications

A Laboratory Prognostic Index Model for Patients with Advanced Non-Small Cell Lung Cancer

A Laboratory Prognostic Index Model for Patients with Advanced Non-Small Cell Lung Cancer

Pretreatment Serum Albumin Level is an Independent Prognostic Factor in Patients with Stage IIIB Non-Small Cell Lung Cancer: A Study of the Turkish Descriptive Oncological Researches Group

Prognostic value of serum cytokeratin 19 fragments (Cyfra 21-1) in patients with non-small cell lung cancer

Contact Info

Product

Resources

About